177 related articles for article (PubMed ID: 37272953)
21. Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.
Lodde GC; Jansen P; Möller I; Sucker A; Hassel JC; Forschner A; Eckardt J; Meier F; Reinhardt L; Kähler KC; Ziemer M; Schlaak M; Rahimi F; Schatton K; Meiss F; Gutzmer R; Pföhler C; Terheyden P; Schilling B; Sachse M; Heppt MV; Sindrilaru A; Leiter U; Zaremba A; Thielmann CM; Ugurel S; Zimmer L; Hadaschik E; Bechrakis NE; Schadendorf D; Westekemper H; Livingstone E; Griewank KG;
Eur J Cancer; 2022 May; 166():60-72. PubMed ID: 35279471
[TBL] [Abstract][Full Text] [Related]
22. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
23. Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging.
Maurer A; Gstrein NA; Dimitriou F; Sartoretti T; Schaab JA; Looman EL; Balermpas P; Rupp NJ; Freiberger SN; Soyka MB; Holzmann D; Mauthe T; Mueller SA; Beintner-Skawran S; Messerli M; Kenkel D; Huellner MW; Meerwein CM
Sci Rep; 2023 Nov; 13(1):18847. PubMed ID: 37914764
[TBL] [Abstract][Full Text] [Related]
24. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract][Full Text] [Related]
25. Primary tumor volume as a predictor of distant metastases and survival in patients with sinonasal mucosal melanoma.
Flukes S; Lohia S; Barker CA; Cracchiolo JR; Ganly I; Patel SG; Roman BR; Shah JP; Shoushtari AN; Tabar V; Shah A; Cohen MA
Head Neck; 2020 Nov; 42(11):3316-3325. PubMed ID: 32737953
[TBL] [Abstract][Full Text] [Related]
26. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
27. Recurrence patterns among patients with sinonasal mucosal melanoma: A multi-institutional study.
Pandrangi VC; Mace JC; Abiri A; Adappa ND; Beswick DM; Chang EH; Eide JG; Fung N; Hong M; Johnson BJ; Kohanski MA; Kshirsagar RS; Kuan EC; Le CH; Lee JT; Nabavizadeh SA; Obermeyer IP; Palmer JN; Pinheiro-Neto CD; Smith TL; Snyderman CH; Suh JD; Wang EW; Wang MB; Choby G; Geltzeiler M
Int Forum Allergy Rhinol; 2023 Dec; 13(12):2156-2164. PubMed ID: 37265013
[TBL] [Abstract][Full Text] [Related]
28. Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.
Spillane S; Baxi S; Torres AZ; Lenis D; Freedman AN; Mariotto AB; Sharon E
Oncologist; 2020 Nov; 25(11):e1753-e1762. PubMed ID: 33094874
[TBL] [Abstract][Full Text] [Related]
29. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
Zhang W; Kong Y; Li Y; Shi F; Lyu J; Sheng C; Wang S; Wang Q
Front Immunol; 2021; 12():798474. PubMed ID: 35087523
[TBL] [Abstract][Full Text] [Related]
30. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis.
Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Lee EQ; Aizer AA; Guenette JP; Huang RY
Korean J Radiol; 2021 Apr; 22(4):584-595. PubMed ID: 33289357
[TBL] [Abstract][Full Text] [Related]
32. Treatment modalities in sinonasal mucosal melanoma: A national cancer database analysis.
Ganti A; Raman A; Shay A; Kuhar HN; Auger SR; Patel T; Kuan EC; Diaz AZ; Batra PS; Tajudeen BA
Laryngoscope; 2020 Feb; 130(2):275-282. PubMed ID: 31021415
[TBL] [Abstract][Full Text] [Related]
33. Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
Bouchereau S; Chaplain L; Fort M; Beauchet A; Sidibé T; Chapalain M; Gonzalez-Lara L; Longvert C; Blom A; Saiag P; Funck-Brentano E
Br J Cancer; 2021 Sep; 125(7):948-954. PubMed ID: 34262147
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
Leiter U; Loquai C; Reinhardt L; Rafei-Shamsabadi D; Gutzmer R; Kaehler K; Heinzerling L; Hassel JC; Glutsch V; Sirokay J; Schlecht N; Rübben A; Gambichler T; Schatton K; Pfoehler C; Franklin C; Terheyden P; Haferkamp S; Mohr P; Bischof L; Livingstone E; Zimmer L; Weichenthal M; Schadendorf D; Meiwes A; Keim U; Garbe C; Becker JC; Ugurel S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093156
[TBL] [Abstract][Full Text] [Related]
36. Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases.
Lauko A; Kotecha R; Barnett A; Li H; Tatineni V; Ali A; Patil P; Mohammadi AM; Chao ST; Murphy ES; Angelov L; Suh JH; Barnett GH; Pennell NA; Ahluwalia MS
Sci Rep; 2021 Sep; 11(1):18174. PubMed ID: 34518623
[TBL] [Abstract][Full Text] [Related]
37. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
38. Survival benefits from concomitant chemoradiotherapy before radical surgery in stage IVA sinonasal mucosal melanoma?
Hafström A; Brun E; Persson S; Sjövall J; Wahlberg P; Greiff L
Laryngoscope Investig Otolaryngol; 2019 Dec; 4(6):624-631. PubMed ID: 31890880
[TBL] [Abstract][Full Text] [Related]
39. Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma.
Amit M; Tam S; Abdelmeguid AS; Roberts DB; Raza SM; Su SY; Kupferman ME; DeMonte F; Hanna EY
Cancer; 2018 Feb; 124(3):514-520. PubMed ID: 29044491
[TBL] [Abstract][Full Text] [Related]
40. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
